Efficacy and Safety of Daridorexant in Older and Younger Adults with Insomnia Disorder: A Secondary Analysis of a Randomised Placebo-Controlled Trial.

ABSTRACT:

Background and objective

The dual orexin receptor antagonist daridorexant, studied in two phase III trials, dose-dependently improved objective and subjective sleep variables and daytime functioning in adults with insomnia. Because treatment of insomnia in older adults is challenging and has limited options, the purpose of the current analysis was to further analyse the phase III trial studying the higher doses of daridorexant, those that showed efficacy (daridorexant 50 mg, daridorexant 25 mg and placebo, nightly for 3 months), and compare the safety and efficacy of daridorexant in patients aged ≥ 65 ('older adults') to those aged < 65 years ('younger adults').

Methods

Analyses by age (≥ 65 years, n = 364; < 65 years, n = 566) were performed on data from the randomised, dou

SUBMITTER: Fietze I 

PROVIDER: S-EPMC9553778 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature